Literature DB >> 18685487

The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker.

Neriman Gokden1, Murat Gokden, Dan C Phan, Jesse K McKenney.   

Abstract

PAX-2 is a homeogene expressed during kidney development. Although immunohistochemical expression of PAX-2 has been described in a variety of primary renal cell carcinoma (RCC) subtypes and in metastatic RCC, its specificity as a marker of renal lineage in a metastatic setting has not been fully evaluated. In addition, its utility has not been directly compared with the most widely used antibody in this setting, renal cell carcinoma marker (RCCma). We studied PAX-2 expression in metastatic clear cell renal cell carcinoma (CC-RCC) and in a variety of nonrenal neoplasms with clear cytoplasm that may potentially mimic CC-RCC. Archival material from 27 CC-RCCs metastatic to various organs and 50 close morphologic mimics of CC-RCC were retrieved. Immunohistochemistry with PAX-2 and RCCmapi antibodies was performed on each case. Nuclear staining (PAX-2) or membranous staining (RCCma) was scored semiquantitatively. Twenty-three of 27 (85%) metastatic CC-RCCs showed nuclear immunoreactivity for PAX-2, whereas RCCma reactivity was found in 19 of 27 (70%). The immunoprofiles of the metastatic CC-RCC were PAX-2+/RCCma+: 19 of 27 (70%), PAX-2+/RCCma-: 5 of 27 (19%), PAX-2-/RCCma+: 2 of 27 (7%), and PAX-2-/RCCma-: 1 of 27 (4%). Five of the 50 mimics of CC-RCC (10%) had at least focal nuclear reactivity with PAX-2, including 1 of 3 parathyroid carcinomas (33%), 3 of 7 clear cell carcinomas of the ovary (43%), and the 1 clear cell papillary cystadenoma of the epididymis. Membranous RCCma reactivity was identified in 26 of the 50 mimics (52%). We conclude that PAX-2 is a useful marker for distinguishing metastatic CC-RCC from its potential morphologic mimics, but caution must be used in certain differential diagnostic settings where nonrenal tumors such as parathyroid carcinoma, ovarian clear cell carcinoma, and clear cell papillary cystadenoma of the epididymis were shown to express both PAX-2 and RCCma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18685487     DOI: 10.1097/PAS.0b013e318176dba7

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  11 in total

Review 1.  Water-clear parathyroid adenoma: report of two cases and literature review.

Authors:  Shuting Bai; Virginia A LiVolsi; Douglas L Fraker; Zhanyong Bing
Journal:  Endocr Pathol       Date:  2012-09       Impact factor: 3.943

2.  Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases.

Authors:  Ankur R Sangoi; Mika Fujiwara; Robert B West; Kelli D Montgomery; Joseph V Bonventre; John P Higgins; Robert V Rouse; Neriman Gokden; Jesse K McKenney
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

3.  Identification of Pax protein inhibitors that suppress target gene expression and cancer cell proliferation.

Authors:  Shayna T J Bradford; Edward Grimley; Ann M Laszczyk; Pil H Lee; Sanjeevkumar R Patel; Gregory R Dressler
Journal:  Cell Chem Biol       Date:  2021-11-24       Impact factor: 8.116

4.  Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma.

Authors:  Jérôme Verine; Jacqueline Lehmann-Che; Hany Soliman; Jean-Paul Feugeas; Jean-Sébastien Vidal; Pierre Mongiat-Artus; Stéphanie Belhadj; Josette Philippe; Matthieu Lesage; Evelyne Wittmer; Stéphane Chanel; Anne Couvelard; Sophie Ferlicot; Nathalie Rioux-Leclercq; Jean-Michel Vignaud; Anne Janin; Stéphane Germain
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

5.  Metastatic renal cell carcinoma presenting as gastric polyps: A case report and review of the literature.

Authors:  Jie Xu; Sahibzada Latif; Shi Wei
Journal:  Int J Surg Case Rep       Date:  2012-08-24

6.  Prospero and Pax2 combinatorially control neural cell fate decisions by modulating Ras- and Notch-dependent signaling.

Authors:  Mark Charlton-Perkins; S Leigh Whitaker; Yueyang Fei; Baotong Xie; David Li-Kroeger; Brian Gebelein; Tiffany Cook
Journal:  Neural Dev       Date:  2011-05-03       Impact factor: 3.842

7.  Gastric Metastasis from Renal Cell Carcinoma, Clear Cell Type, Presenting with Gastrointestinal Bleeding.

Authors:  Mouhanna Abu Ghanimeh; Ayman Qasrawi; Omar Abughanimeh; Sakher Albadarin; John H Helzberg
Journal:  Case Rep Gastrointest Med       Date:  2017-08-29

8.  Pseudolaric acid B inhibits PAX2 expression through Wnt signaling and induces BAX expression, therefore promoting apoptosis in HeLa cervical cancer cells.

Authors:  Defeng Guan; Chenyang Li; Xiao Lv; Yongxiu Yang
Journal:  J Gynecol Oncol       Date:  2019-09       Impact factor: 4.401

9.  Congenital Anomalies of the Kidney and Urinary Tract and Adulthood risk of Urinary Tract Cancer.

Authors:  Ronit Calderon-Margalit; Gil Efron; Oren Pleniceanu; Dorit Tzur; Michal Stern-Zimmer; Arnon Afek; Tomer Erlich; Estela Derazne; Jeremy D Kark; Lital Keinan-Boker; Gilad Twig; Asaf Vivante
Journal:  Kidney Int Rep       Date:  2021-01-10

10.  An integrated epigenome and transcriptome analysis identifies PAX2 as a master regulator of drug resistance in high grade pancreatic ductal adenocarcinoma.

Authors:  Imlimaong Aier; Rahul Semwal; Aiindrila Dhara; Nirmalya Sen; Pritish Kumar Varadwaj
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.